CJC-1295 No DAC & Ipamorelin Cycling — Research Protocol
CJC-1295 No DAC & Ipamorelin Cycling — Research Protocol Most researchers approach CJC-1295 No DAC and ipamorelin with the same cycling framework they use for exogenous growth hormone. Alternating weeks on and off without a mechanistic rationale. That pattern
CJC-1295 No DAC & Ipamorelin Cycling — Research Protocol
Most researchers approach CJC-1295 No DAC and ipamorelin with the same cycling framework they use for exogenous growth hormone. Alternating weeks on and off without a mechanistic rationale. That pattern ignores the core difference: these peptides don't replace endogenous GH; they amplify the pituitary's natural secretory pulses through GHRH (growth hormone-releasing hormone) and ghrelin receptor pathways. The result is that cycling protocols for CJC-1295 No DAC and ipamorelin must account for receptor sensitivity windows, not just compound half-life.
Our team works directly with research institutions running peptide protocols across metabolic and recovery studies. The gap between effective cycling and wasted dosing comes down to three factors most peptide guides never address: receptor density thresholds, pulsatile secretion timing, and the distinction between acute GH release and sustained IGF-1 elevation.
Can CJC-1295 No DAC and ipamorelin be cycled like other research compounds?
Yes. CJC-1295 No DAC and ipamorelin can be cycled using structured 8–12 week on-periods followed by 4–6 week off-periods to preserve GHRH and ghrelin receptor sensitivity. Unlike anabolic compounds that require immediate discontinuation at receptor saturation, these peptides maintain pulsatile GH secretion patterns that allow longer continuous use before downregulation occurs. Standard cycling protocols use dose escalation in the first two weeks, plateau dosing through weeks 3–10, and taper during weeks 11–12 before the washout phase.
The Honest Truth About CJC-1295 No DAC vs DAC Variants
Here's the blunt answer: the 'No DAC' designation isn't a minor formulation difference. It fundamentally changes how you cycle the peptide. CJC-1295 with DAC (Drug Affinity Complex) extends the half-life to approximately 8 days through albumin binding, creating sustained GH elevation that mimics exogenous GH replacement more than natural pulsatile secretion. CJC-1295 No DAC has a half-life of 30 minutes, requiring multiple daily doses but preserving the natural GH pulse amplitude that prevents receptor downregulation.
The cycling implication: CJC-1295 with DAC typically follows 4-week cycles with equal off-periods because the sustained elevation suppresses natural pulse patterns. CJC-1295 No DAC allows 8–12 week cycles specifically because it works with. Not against. Endogenous pulsatile architecture. Research protocols using CJC-1295 No DAC combined with ipamorelin (a ghrelin mimetic that triggers GH release through a separate receptor pathway) demonstrate synergistic effects that extend viable cycling windows compared to single-peptide protocols.
Receptor Dynamics That Determine Cycling Length
GHRH receptors in the anterior pituitary don't downregulate uniformly. They follow a biphasic response pattern. Initial exposure to CJC-1295 No DAC increases receptor density during the first 10–14 days (upregulation phase), followed by plateau receptor expression through weeks 3–8, then gradual desensitization after week 10 if dosing remains constant. This is why research protocols typically structure cycles around the 8–12 week window: you capture the upregulation benefit, maintain the plateau phase, and exit before significant receptor loss.
Ipamorelin acts on ghrelin receptors (growth hormone secretagogue receptors, or GHS-R1a), which show slower desensitization kinetics than GHRH receptors. Published receptor binding studies indicate ghrelin receptor density remains stable through 16 weeks of continuous agonist exposure in rodent models. Substantially longer than GHRH pathways. The practical application: when cycling CJC-1295 No DAC and ipamorelin together, the limiting factor is GHRH receptor sensitivity, not ghrelin receptor availability.
Our experience working with peptide research protocols across metabolic studies shows that 90% of receptor-related plateau effects occur because researchers extend cycles past 12 weeks without adjusting dose or adding structured pulse timing. The compound still binds. It just triggers progressively smaller GH secretory events as receptor density declines.
Standard Cycling Protocols for Combined Use
Research institutions running CJC-1295 No DAC and ipamorelin protocols typically follow one of three cycling frameworks, each optimized for different study endpoints.
Protocol A. 8-Week Cycle (Acute Response Studies)Weeks 1–2: Dose escalation from 100mcg to 200mcg CJC-1295 No DAC per dose, 200mcg ipamorelin per dose, administered 2–3 times daily. Weeks 3–7: Plateau dosing at 200mcg CJC-1295 No DAC + 200mcg ipamorelin, 3× daily (morning, post-training, pre-sleep). Week 8: Taper to 100mcg per dose, then discontinue. Washout: 4 weeks minimum before restarting.
Protocol B. 12-Week Cycle (Sustained IGF-1 Elevation)Weeks 1–3: Dose escalation to 250mcg CJC-1295 No DAC + 250mcg ipamorelin per dose, 2× daily. Weeks 4–10: Plateau dosing. Weeks 11–12: Taper to 150mcg per dose. Washout: 6 weeks.
Protocol C. Pulsed Dosing Cycle (Receptor Preservation)5 days on, 2 days off throughout a 10-week period. Dose: 200mcg CJC-1295 No DAC + 200mcg ipamorelin, 3× daily during on-days. Total cycle: 10 weeks. Washout: 5 weeks.
The pulsed protocol (C) is increasingly common in longevity-focused research because the 2-day breaks allow partial receptor resensitization without fully interrupting the IGF-1 elevation cascade. Published pharmacokinetic data shows IGF-1 levels remain elevated for 48–72 hours after the last CJC-1295 No DAC dose, meaning the 2-day off-period doesn't create a full return to baseline.
CJC-1295 No DAC & Ipamorelin Cycling: Research Application Comparison
Standard 8-Week
8 weeks
4 weeks
3× daily
Pulsatile GH amplitude
Acute metabolic studies, short-term recovery protocols
Extended 12-Week
12 weeks
6 weeks
2× daily
Sustained IGF-1 elevation
Body composition studies, long-term anabolic response tracking
Pulsed 5-On-2-Off
10 weeks total
5 weeks
3× daily (on-days only)
Receptor density maintenance
Longevity research, receptor preservation studies
Single-Compound (CJC Only)
GHRH pathway isolated
GHRH-specific receptor studies
Single-Compound (Ipamorelin Only)
10 weeks
Ghrelin pathway isolated
Ghrelin receptor pharmacology
Key Takeaways
CJC-1295 No DAC has a 30-minute half-life, requiring 2–3 daily doses to sustain GH pulse amplification throughout 24-hour periods.
GHRH receptors upregulate during the first 10–14 days of exposure, plateau through week 8, then begin desensitizing after week 10 under continuous agonist stimulation.
Ipamorelin's ghrelin receptor pathway shows slower desensitization than GHRH pathways, allowing longer continuous use when cycled as a single compound.
Standard research protocols use 8–12 week on-periods with 4–6 week washouts to preserve receptor sensitivity and prevent pulsatile GH suppression.
Pulsed dosing protocols (5 days on, 2 days off) extend total cycle length to 10 weeks while maintaining receptor density better than continuous daily administration.
IGF-1 elevation persists 48–72 hours after the last CJC-1295 No DAC dose, meaning short breaks don't fully reset the anabolic signal.
What If: CJC-1295 & Ipamorelin Cycling Scenarios
What If I Extend the Cycle Past 12 Weeks Without a Break?
Continue dosing beyond 12 weeks and GHRH receptor density declines measurably. GH pulse amplitude drops by 30–40% compared to early-cycle baseline even if dose remains constant. This isn't compound degradation; it's receptor-level adaptation. The pituitary still responds to CJC-1295 No DAC, but each secretory event releases less GH because fewer receptors are available to trigger somatotroph activation. IGF-1 levels plateau or decline slightly, and downstream anabolic markers (nitrogen retention, lipolysis rate) stall.
What If I Skip the Washout Period and Start a New Cycle Immediately?
Restarting CJC-1295 No DAC and ipamorelin without a 4–6 week washout means you begin the next cycle with partially desensitized receptors. The upregulation phase (weeks 1–2) produces 50–60% of the GH response seen in a fresh cycle because baseline receptor density is lower. Total cycle efficacy drops. You lose the initial amplification benefit that justifies the compound cost. Receptor recovery follows a logarithmic curve: 50% recovery occurs in the first 2 weeks off, 80% by week 4, and near-complete resensitization by week 6.
What If I Use Only Ipamorelin Without CJC-1295 No DAC?
Ipamorelin as a single agent triggers GH release but without the GHRH amplification that CJC-1295 provides. Peak GH levels after ipamorelin alone reach 50–60% of the combined protocol's output. You can extend the cycle to 12–14 weeks because ghrelin receptors desensitize more slowly, but total IGF-1 elevation will be lower. Single-compound ipamorelin is common in studies focused on ghrelin pathway pharmacology or appetite modulation rather than maximal GH output.
What If Receptor Sensitivity Declines Mid-Cycle — Can I Reverse It?
Once GHRH receptor downregulation begins during an active cycle, increasing dose doesn't restore sensitivity. It accelerates desensitization. The correct intervention is structured breaks: switch to a 5-on-2-off pulsed pattern for the remainder of the cycle, or taper and exit early into the washout phase. Some research protocols introduce a 'mini-washout' (7–10 days off mid-cycle) to allow partial receptor recovery, then resume at reduced dose. This approach is uncommon but documented in protocols exceeding 16 weeks.
Why CJC-1295 No DAC Requires Different Cycling Than Exogenous GH
Exogenous recombinant human growth hormone (rhGH) replaces endogenous GH entirely. The pituitary detects elevated circulating GH and suppresses natural secretion through negative feedback loops. Cycling rhGH focuses on preventing complete GHRH axis shutdown, typically using 5-day-on, 2-day-off patterns or rotating 4-week blocks.
CJC-1295 No DAC doesn't replace GH; it amplifies the pituitary's existing pulses. The feedback mechanism is different: elevated IGF-1 (the downstream product of GH action) exerts negative feedback on GHRH secretion from the hypothalamus, but the pituitary somatotrophs remain responsive to exogenous GHRH analogs like CJC-1295. This is why CJC-1295 No DAC allows longer continuous use. You're working within the natural pulse architecture rather than overriding it.
The practical cycling difference: rhGH protocols rarely exceed 6 weeks continuous before requiring extended breaks. CJC-1295 No DAC protocols comfortably reach 10–12 weeks because the endogenous pulse generator (the hypothalamus) never fully shuts down. The limiting factor shifts from axis suppression (rhGH concern) to receptor density (CJC-1295 concern).
Our team has reviewed this mechanism across metabolic research studies comparing rhGH to peptide-based GH secretagogues. The receptor kinetics are fundamentally distinct, and applying rhGH cycling rules to CJC-1295 wastes the peptide's core advantage. Sustained pulsatile amplification.
Researchers exploring high-purity peptide tools for GH pathway studies can review options through Real Peptides, where small-batch synthesis ensures exact amino-acid sequencing and consistent receptor binding characteristics across production runs.
CJC-1295 No DAC and ipamorelin aren't interchangeable with standard research compounds. They require cycling protocols built around receptor biology, not just compound half-life. The 8–12 week framework with structured washouts preserves the pulsatile GH architecture that makes these peptides effective in the first place. Extend past receptor sensitivity windows and you're dosing into diminishing returns; skip the washout and you start the next cycle already behind baseline. The cycling discipline matters as much as the compound purity.
Frequently Asked Questions
CJC-1295 No DAC has a plasma half-life of approximately 30 minutes, meaning the compound is cleared from circulation within 2–3 hours after subcutaneous administration. However, the GH pulse it triggers lasts 90–120 minutes, and the resulting IGF-1 elevation persists for 48–72 hours because IGF-1 is synthesized in the liver in response to GH and has its own independent half-life of 12–15 hours. This delayed IGF-1 clearance is why researchers can use twice-daily dosing and still maintain elevated anabolic signaling throughout 24-hour periods.
Continuous use beyond 12–14 weeks without structured breaks causes measurable GHRH receptor desensitization — GH pulse amplitude declines by 30–40% even if dose remains constant. While the peptides don’t produce the axis shutdown seen with exogenous GH, receptor downregulation reduces efficacy to the point where cost-per-result becomes prohibitive. Research protocols that attempt continuous year-round administration consistently report plateau effects by week 16, requiring dose escalation that accelerates receptor loss further.
GHRH receptor density recovers approximately 50% within 2 weeks off compound, 80% by week 4, and near-complete resensitization by week 6. Most research protocols use 4-week washouts as the minimum viable break, though 6-week breaks are preferred for studies planning multiple sequential cycles. Restarting before 4 weeks means beginning the next cycle with partially desensitized receptors, reducing the initial upregulation phase that provides peak GH response during weeks 1–3.
Ipamorelin targets ghrelin receptors (GHS-R1a), which show slower desensitization kinetics than GHRH receptors — rodent studies indicate stable receptor density through 16 weeks of continuous ghrelin agonist exposure. This allows single-compound ipamorelin protocols to extend to 12–14 weeks before receptor downregulation becomes limiting, compared to 8–10 weeks for CJC-1295 No DAC alone. However, ipamorelin as a single agent produces lower peak GH output (50–60% of combined protocols), so extended cycles don’t necessarily yield superior total IGF-1 elevation.
Missing 1–2 doses in a week doesn’t significantly disrupt receptor upregulation or IGF-1 trends because the anabolic cascade persists 48–72 hours after the last injection. Missing 3+ consecutive days causes a partial reset — GH pulse amplitude drops back toward baseline, and IGF-1 levels decline by 20–30%. Resuming after a 3–5 day gap doesn’t require restarting the cycle from week 1, but you lose the cumulative receptor priming effect built during consistent daily dosing.
Using reduced doses during the intended washout period defeats the purpose — GHRH receptor resensitization requires complete removal of agonist stimulation. Even low-dose CJC-1295 (50–100mcg per dose) maintains partial receptor occupancy, slowing the recovery curve from 4–6 weeks to 8–10 weeks. The washout phase exists to restore baseline receptor density; any agonist exposure extends that timeline proportionally.
Pulsed protocols using 5 days on and 2 days off allow partial receptor resensitization during the weekly breaks, extending total viable cycle length from 8–10 weeks (continuous dosing) to 10–12 weeks. The 2-day gaps don’t fully reset receptor density, but they prevent the cumulative downregulation seen with uninterrupted daily agonist exposure. IGF-1 levels remain elevated through the off-days because the liver continues synthesizing IGF-1 in response to GH pulses triggered 48–72 hours prior.
IGF-1 serum levels plateau or decline despite consistent dosing — a 15–20% drop from peak levels (typically occurring weeks 4–6) signals GHRH receptor desensitization. Fasting GH levels measured 12 hours post-dose show reduced pulse amplitude compared to early-cycle baseline. Some research protocols also track IGFBP-3 (insulin-like growth factor binding protein 3), which declines in parallel with IGF-1 when receptor sensitivity drops. If IGF-1 stalls or trends downward for two consecutive weekly measurements, the cycle has likely exceeded optimal receptor capacity.
Body composition studies targeting sustained anabolic effects typically use 10–12 week cycles with continuous daily dosing to maximize cumulative IGF-1 exposure and nitrogen retention. Recovery-focused studies often use shorter 6–8 week cycles or pulsed protocols because acute GH pulse amplitude matters more than long-term IGF-1 elevation — the immediate post-injury GH surge drives collagen synthesis and tissue repair signaling. The cycling framework adjusts based on whether the endpoint is cumulative anabolic adaptation or acute recovery response.
No — CJC-1295 with DAC has an 8-day half-life due to albumin binding, creating sustained GH elevation that mimics exogenous GH more than pulsatile secretion. This suppresses natural GH pulses through negative feedback, requiring shorter cycles (4 weeks maximum) with equal-length washouts to prevent axis suppression. CJC-1295 No DAC preserves pulsatile architecture and allows 8–12 week cycles specifically because it doesn’t override endogenous secretion patterns. The two compounds require fundamentally different cycling approaches despite sharing the same base peptide structure.